NEW YORK (GenomeWeb) – KalGene Pharmaceuticals has inked an agreement with three Canadian research entities, the Sunnybrook Research Institute, the Centre for Imaging Technology Commercialization, and the Ontario Cancer Biomarker Network, to develop a companion diagnostic for metastatic cancer.

The Vancouver, British Columbia-based pharmaceutical firm will collaborate with its partners on a prognostic marker test along with a companion therapeutic specifically targeting aggressive cancers, such as metastatic breast, colon, and brain cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.